Stock Analysis of 180 Life Sciences Corp (ATNF) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code ATNF
Close 1.58
Change -0.070 / 4.24 %
Volume 49415.00
Vol Change -68555.00 / 58.11 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthStrong Bearish
Growth Index Poor Growth Stock
Value Index Poor Value Stock
Profitability Index Poor Profitability Stock
Stability Index Poor Stability Stock


Fundamental View of 180 Life Sciences Corp
PE (TTM)

-0.0454

Very Poor
Price / Book

0.292

Excellent
Price / Sales

4.44

Very Poor
Piotroski F Score

2.0

Poor
Market Cap

1448.21 K

Enterprise Value

-941673.53 M

ROA (TTM)

-192.23

Very Poor
ROE (TTM)

-643.32

Very Poor
Net Margin (TTM)

-9783.04

Very Poor
Revenue

%

0
Net Profit

4.45 %

-40450.29 K
Debt to Equity

-8.10

Very Poor
Altman Z Score

-33.90

Very Poor
Quick Ratio

0

Poor
Cash Ratio

0.390

Poor


Highs/Lows of 180 Life Sciences Corp
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week1.93 18.13 % 1.54 % 2.19391.440113-May-2416-May-24
Two Week2.0 21.00 % 3.42 % 2.31.440107-May-2416-May-24
One Month1.91 17.28 % 5.60 % 2.31.440107-May-2416-May-24
Three Month3.9007 59.49 % 5.95 % 4.751.3320-Feb-2416-Apr-24
Six Months6.859 76.96 % 17.48 % 7.80521.3320-Nov-2316-Apr-24
One year18.5915 91.50 % 27.52 % 27.931.3319-May-2316-Apr-24
Two year478.8 99.67 % 29.70 % 342.01.3307-Oct-2216-Apr-24
Five year3971.0 99.96 % 85.46 % 55.10.150102-Mar-2318-Dec-23


Technical View of 180 Life Sciences Corp
RSI

35.50

Neutral
MACD

-0.134

Mild Bullish
ADX

15.98

Bearish
Super Trend

2.36

Mild Bearish
Williams %R

-83.73

Mild Bearish
CCI

-206.44

Mild Bullish


EMA 5

1.77

Strong Bearish
EMA 15

1.90

Strong Bearish
EMA 50

2.37

Strong Bearish
EMA 100

3.79

Mild Bearish
SMA 100

3.11

Mild Bearish
SMA 200

6.23

Strong Bearish
SMA 5 / 20

1.84 / 1.91

Strong Bearish
SMA 15 / 50

1.94 / 2.33

Mild Bearish
SMA 50 / 200

2.33 / 6.23

Strong Bearish




Charts of 180 Life Sciences Corp


Returns of 180 Life Sciences Corp with Peers
Period / StockATNFPEARINFINBSE
1 Week-18.13%-63.01%-23.81%-6.67%
1 Mth-17.28%-95.85%-80.15%-5.78%
3 Mth-59.49%-99.00%-92.38%-44.41%
6mth-76.96%-99.62%-91.58%-43.95%
1 Year-91.50%-99.80%-98.66%-90.05%
2 Year-99.67%-99.89%-99.52%-98.07%
5 Years-99.96%--99.41%-99.26%
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of 180 Life Sciences Corp with Peers
Ratio / StockATNFPEARINFINBSE
PE-0.0454-0.0162-9.00-0.0233
P/B0.2920.0236-18.630.0209
ROA-192.23-64.60-96.89-56.60
ROE-643.32-145.870-89.59
Debt To Equity-8.100.065-0.03110.0285
Revenue0
% 		12694.00 K
201.66 % 		2593.00 K
39.56 % 		0
%
Net Income-40450.29 K
4.45 % 		-75491.00 K
15.89 % 		-43256.00 K
4.43 % 		-33776.45 K
32.93 %


Technicals of 180 Life Sciences Corp with Peers
Technical / StockATNFPEARINFINBSE-
ADX15.9846.8539.5823.02
CMF-0.103-0.617-0.324-0.100
MFI48.6951.482.0313.69
RSI35.5020.2226.2330.84
MACD Abv SignalTrueTrueFalseTrue
Price Above 50 MAFalseFalseFalseFalse-
Price Above 200 MAFalseFalseFalseFalse-


About : 180 Life Sciences Corp

Address : Building 4, Palo Alto, CA, United States, 94306
Tel : 650 507 0669
URL : https://180lifesciences.com
Code : ATNF, ISIN : US68236V1044, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 27_Jun_2017
Employee Count : 4

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren's Contracture; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, that focuses on alpha 7 nicotinic acetylcholine receptor. The company is headquartered in Palo Alto, California.


Note : All Data Generated at the End of Trading Hours (EOD Data)